151 related articles for article (PubMed ID: 37872123)
21. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
[TBL] [Abstract][Full Text] [Related]
22. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
Pelosi G; Papotti M; Righi L; Rossi G; Ferrero S; Bosari S; Calabrese F; Kern I; Maisonneuve P; Sonzogni A; Albini A; Harari S; Barbieri F; Capelletto E; Catino AM; Cavone D; De Palma A; Fusco N; Lunardi F; Maiorano E; Marzullo A; Novello S; Papanikolaou N; Pasello G; Pennella A; Pezzuto F; Punzi A; Prisciandaro E; Rea F; Rosso L; Scattone A; Serio G
J Thorac Oncol; 2018 Nov; 13(11):1750-1761. PubMed ID: 30249391
[TBL] [Abstract][Full Text] [Related]
23. Interobserver Agreement in Histopathological Subtyping of Malignant Pleural Mesotheliomas.
Mlika M; Mezni F
Turk Patoloji Derg; 2021; 37(1):56-62. PubMed ID: 32692400
[TBL] [Abstract][Full Text] [Related]
24. Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.
Brcic L; Vlacic G; Quehenberger F; Kern I
Arch Pathol Lab Med; 2018 Jun; 142(6):747-752. PubMed ID: 29509030
[TBL] [Abstract][Full Text] [Related]
25. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
[TBL] [Abstract][Full Text] [Related]
26. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
27. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in malignant pleural mesothelioma.
Davidson B
Hum Pathol; 2015 Jun; 46(6):789-804. PubMed ID: 25824607
[TBL] [Abstract][Full Text] [Related]
29. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
30. Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.
Takeda M; Kasai T; Hatakeyama K; Nakai T; Itami H; Uchiyama T; IIzuka N; Maruyama H; Ohbayashi C
Int J Surg Pathol; 2017 Dec; 25(8):668-673. PubMed ID: 28673192
[TBL] [Abstract][Full Text] [Related]
31. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Galateau-Salle F; Churg A; Roggli V; Travis WD;
J Thorac Oncol; 2016 Feb; 11(2):142-54. PubMed ID: 26811225
[TBL] [Abstract][Full Text] [Related]
32. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
33. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
Alchami FS; Attanoos RL; Bamber AR
J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
Koyuncu A; Koksal D; Ozmen O; Demirag F; Bayiz H; Aydogdu K; Berkoglu M
J Cancer Res Ther; 2015; 11(1):216-22. PubMed ID: 25879365
[TBL] [Abstract][Full Text] [Related]
35. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
Manur R; Lamzabi I
Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.
Krasinskas AM; Borczuk AC; Hartman DJ; Chabot JA; Taub RN; Mogal A; Pingpank J; Bartlett D; Dacic S
Histopathology; 2016 Apr; 68(5):729-37. PubMed ID: 26272336
[TBL] [Abstract][Full Text] [Related]
38. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.
Bilecz A; Stockhammer P; Theegarten D; Kern I; Jakopovic M; Samarzija M; Klikovits T; Hoda MA; Döme B; Oberndorfer F; Muellauer L; Fillinger J; Kovács I; Pirker C; Schuler M; Plönes T; Aigner C; Klepetko W; Berger W; Brcic L; Laszlo V; Hegedus B
Histopathology; 2020 Jul; 77(1):55-66. PubMed ID: 32170970
[TBL] [Abstract][Full Text] [Related]
40. c-Met expression and MET amplification in malignant pleural mesothelioma.
Bois MC; Mansfield AS; Sukov WR; Jenkins SM; Moser JC; Sattler CA; Smith CY; Molina JR; Peikert T; Roden AC
Ann Diagn Pathol; 2016 Aug; 23():1-7. PubMed ID: 27402216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
